XBiotech (XBIT) Completes Monoclonal Antibody Therapy Phase 1/2 as Staph Treatment
Tweet Send to a Friend
XBiotech (NASDAQ: XBIT) announced the completion of the first cohort in its Phase 1/2 clinical study of a novel True ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
